Andreas Peyrl

List of Publications by Year
in descending order

73	1,545	471061 17	344852 36
papers	citations	h-index	g-index

75	75	75	3042
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Unique Finding of a Primary Central Nervous System Neuroendocrine Carcinoma in a 5-Year-Old Child: A Case Report. Frontiers in Neuroscience, 2022, 16, 810645.	1.4	3
2	Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors. Cancer Chemotherapy and Pharmacology, 2022, 89, 617-627.	1.1	3
3	Evaluating the diagnostic validity of the cerebellar cognitive affective syndrome (CCAS) in pediatric posterior fossa tumor patients. Neuro-Oncology Advances, 2022, 4, .	0.4	2
4	QOL-35. School reentry of children and adolescents with a brain tumor: can we improve family-school-hospital cooperation? An analysis of supportive and inhibiting factors as a result of a pilot project. Neuro-Oncology, 2022, 24, i141-i141.	0.6	0
5	DIPG-60. Avapritinib for targeting PDGFRA in H3K27M â€“ mutated diffuse midline glioma. Neuro-Oncology, 2022, 24, i32-i32.	0.6	3
6	HGG-50. Specific sensitivity of pediatric high-grade glioma with ATRX inactivation to PARP inhibitor combinations. Neuro-Oncology, 2022, 24, i73-i73.	0.6	0
7	QOL-27. Sociocultural variables have a major impact on participation in patients treated for pediatric posterior fossa tumors. Neuro-Oncology, 2022, 24, i139-i139.	0.6	0
8	PATH-09. Liquid biopsy of cerebrospinal fluid enables detecting and monitoring ofMYC/MYCN amplification in pediatric CNS malignancies. Neuro-Oncology, 2022, 24, i160-i160.	0.6	0
9	SWK-06. Structured transition from pediatric neuro-oncology to adult survivorship follow-up care - Can we close the gap?. Neuro-Oncology, 2022, 24, i181-i182.	0.6	0
10	DDEL-05. Intraventricular therapy with topotecan is feasible and safe: Experience in 50 pediatric patients with various malignant brain tumors. Neuro-Oncology, 2022, 24, i34-i35.	0.6	0
11	SURG-02. The site of origin of medulloblastoma: Does the neurosurgical perspective support the current concept from molecular data?. Neuro-Oncology, 2022, 24, i142-i142.	0.6	0
12	ETMR-12. Novel cell models of CNS tumors with BCOR fusion or internal tandem duplication suggest FGFR and PDGFR as promising therapy targets. Neuro-Oncology, 2022, 24, i52-i52.	0.6	0
13	GCT-12. SIOP CNS GCT II: High Risk (HR) CNS Non-germinomatous Germ Cell Tumours (NGGCT) treated with Dose intensified PEI â€“ final results. Neuro-Oncology, 2022, 24, i56-i57.	0.6	1
14	QOL-30. Positive Effects of a psychological preparation program for MRI in children with cognitive issues â€“ how to best meet the patientsâ€™ needs. Neuro-Oncology, 2022, 24, i140-i140.	0.6	0
15	GCT-11. 24 Gy whole ventricular radiotherapy alone is sufficient for disease control in localised germinoma in CR after initial chemotherapy â€“ final of the SIOP CNS GCT II study. Neuro-Oncology, 2022, 24, i56-i56.	0.6	0
16	SWK-05. Clinical social work in pediatric neuro-oncology â€“ A research project on the social dimension using social diagnostics. Neuro-Oncology, 2022, 24, i181-i181.	0.6	0
17	QOL-24. Evaluating the diagnostic validity & predictive value of the Cerebellar Cognitive Affective Syndrome (CCAS) in pediatric posterior fossa tumour patients. Neuro-Oncology, 2022, 24, i138-i139.	0.6	0
18	How can we optimize the long-term outcome in children with intracranial cavernous malformations? A single-center experience of 61 cases. Neurosurgical Review, 2022, 45, 3299-3313.	1.2	2

#	Article	IF	Citations
19	Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas. Acta Neurochirurgica, 2021, 163, 2025-2035.	0.9	13
20	Novel Insights into Diagnosis, Biology and Treatment of Primary Diffuse Leptomeningeal Melanomatosis. Journal of Personalized Medicine, 2021, 11, 292.	1.1	15
21	Targeting fibroblast growth factor receptors to combat aggressive ependymoma. Acta Neuropathologica, 2021, 142, 339-360.	3.9	14
22	RARE-20. A RARE CASE OF A PRIMARY CENTRAL NERVOUS SYSTEM NEUROENDOCRINE CARCINOMA AND SUCCESSFULL THERAPY IN A FIVE-YEAR-OLD CHILD. Neuro-Oncology, 2021, 23, i45-i45.	0.6	0
23	Innovative therapy concepts for pediatric brain tumors. Memo - Magazine of European Medical Oncology, 2021, 14, 260-264.	0.3	1
24	Self-Care Strategies and Job Satisfaction in Pediatricians: What We Can Do to Prevent Burnoutâ€"Results of a Nationwide Survey. Frontiers in Pediatrics, 2021, 9, 722356.	0.9	3
25	INNV-17. RESPONSE TO AVAPRITINIB IN A PEDIATRIC SPINAL CORD H3K27M-MUTANT GLIOMA PATIENT. Neuro-Oncology, 2021, 23, vi108-vi108.	0.6	2
26	Predisposition of Wingless Subgroup Medulloblastoma for Primary Tumor Hemorrhage. Neurosurgery, 2020, 86, 478-484.	0.6	2
27	Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. Cancer Cell, 2020, 38, 44-59.e9.	7.7	94
28	Evaluation and optimization of common lipid extraction methods in cerebrospinal fluid samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1153, 122271.	1.2	16
29	An adolescent with herpes simplex encephalitis, presenting with mild symptoms and rapid deterioration: A case report. SAGE Open Medical Case Reports, 2020, 8, 2050313X2097714.	0.2	0
30	Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma. Journal of Personalized Medicine, 2020, 10, 290.	1.1	18
31	Determination of a Tumor-Promoting Microenvironment in Recurrent Medulloblastoma: A Multi-Omics Study of Cerebrospinal Fluid. Cancers, 2020, 12, 1350.	1.7	30
32	Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. Acta Neuropathologica Communications, 2020, 8, 78.	2.4	28
33	Subsequent MRI of pediatric patients after an adverse reaction to Gadolinium-based contrast agents. PLoS ONE, 2020, 15, e0230781.	1.1	7
34	MBCL-43. RECURRENT MEDULLOBLASTOMA â€“ LONG-TERM SURVIVAL WITH A â€œMEMMATâ€•BASED ANTIANGIOGENIC APPROACH. Neuro-Oncology, 2020, 22, iii397-iii397.	0.6	5
35	Potential Importance of Early Focal Radiotherapy Following Gross Total Resection for Long-Term Survival in Children With Embryonal Tumors With Multilayered Rosettes. Frontiers in Oncology, 2020, 10, 584681.	1.3	11
36	DDEL-03. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE: EXPERIENCE IN 75 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS. Neuro-Oncology, 2020, 22, iii284-iii284.	0.6	0

#	Article	IF	Citations
37	ETMR-10. EARLY FOCAL RADIOTHERAPY AND TEMOZOLOMIDE FOLLOWING COMPLETE RESECTION APPEAR SUPERIOR TO INTENSIVE CHEMOTHERAPY AND DELAYED RADIOTHERAPY IN CHILDREN WITH EMBRYONAL TUMORS WITH MULTILAYERED ROSETTES (ETMR). Neuro-Oncology, 2020, 22, iii324-iii325.	0.6	0
38	GCT-76. 24Gy WHOLE VENTRICULAR RADIOTHERAPY ALONE IS SUFFICIENT FOR DISEASE CONTROL IN LOCALISED GERMINOMA IN CR AFTER INITIAL CHEMOTHERAPY â€“ EARLY RESULTS OF THE SIOP CNS GCT II STUDY. Neuro-Oncology, 2020, 22, iii343-iii344.	0.6	8
39	EPEN-21. IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION IN PEDIATRIC EPENDYMOMA REVEALED BY SINGLE-CELL RNA-SEQ. Neuro-Oncology, 2020, 22, iii311-iii312.	0.6	0
40	HGG-44. DEFECTS OF MISMATCH REPAIR PROTEINS IN PEDIATRIC HIGH GRADE GLIOMAS. Neuro-Oncology, 2020, 22, iii351-iii352.	0.6	0
41	EPCO-35. SINGLE-CELL RNA-SEQ OF PEDIATRIC EPENDYMOMA REVEALS PROGNOSTIC IMPACT OF IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION. Neuro-Oncology, 2020, 22, ii76-ii77.	0.6	0
42	TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma. Acta Neuropathologica Communications, 2019, 7, 128.	2.4	26
43	Resolving medulloblastoma cellular architecture by single-cell genomics. Nature, 2019, 572, 74-79.	13.7	273
44	High impact of miRNA-4521 on FOXM1 expression in medulloblastoma. Cell Death and Disease, 2019, 10, 696.	2.7	27
45	Laser Ablation-Inductively Coupled Plasma Time-of-Flight Mass Spectrometry Imaging of Trace Elements at the Single-Cell Level for Clinical Practice. Analytical Chemistry, 2019, 91, 8207-8212.	3.2	41
46	RARE-12. EARLY FOCAL RADIOTHERAPY AND TEMOZOLOMIDE FOLLOWING COMPLETE RESECTION APPEAR SUPERIOR TO INTENSIVE CHEMOTHERAPY IN CHILDREN WITH EMBRYONAL TUMORS WITH MULTILAYERED ROSETTES (ETMR). Neuro-Oncology, 2019, 21, vi223-vi224.	0.6	0
47	PDTM-32. RESOLVING MEDULLOBLASTOMA CELLULAR ARCHITECTURE BY SINGLE-CELL GENOMICS. Neuro-Oncology, 2019, 21, vi194-vi194.	0.6	0
48	Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities. Frontiers in Oncology, 2019, 9, 1436.	1.3	50
49	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science, 2018, 360, 331-335.	6.0	461
50	Does the interval from tumour surgery to radiotherapy influence survival in paediatric high grade glioma?. Strahlentherapie Und Onkologie, 2018, 194, 552-559.	1.0	7
51	Brain tumors â€“ other treatment modalities. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 547-560.	1.0	2
52	Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [¹⁸F]FDGâ€PET imaging. Is it of value in asymptomatic patients?. Pediatric Blood and Cancer, 2018, 65, e26733.	0.8	35
53	EAPH-11. INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE, AQUEOUS CYTARABINE AND TOPOTECAN IS FEASIBLE AND SAFE: EXPERIENCE IN 26 PEDIATRIC PATIENTS WITH MALIGNANT BRAIN TUMORS. Neuro-Oncology, 2018, 20, i67-i67.	0.6	2
54	MBCL-28. PREDISPOSITION OF WNT-ACTIVATED MEDULLOBLASTOMA FOR PRIMARY INTRATUMORAL HEMORRHAGE. Neuro-Oncology, 2018, 20, i122-i122.	0.6	0

#	Article	IF	Citations
55	MBCL-40. UNFAVORABLE CLINICAL COURSE OF A WNT-ACTIVATED MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i125-i126.	0.6	0
56	NSRG-19. CSF DISTURBANCES AFTER TRANSCALLOSAL RESECTION: ARE THERE PREDICTING FACTORS?. Neuro-Oncology, 2018, 20, i149-i149.	0.6	0
57	INNV-36. A METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY MAY PROLONG SURVIVAL FOR PATIENTS WITH RECURRENT MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR. Neuro-Oncology, 2018, 20, vi145-vi145.	0.6	0
58	MBCL-27. RESPONSE OF RECURRENT MALIGNANT CHILDHOOD CNS TUMORS TO A MEMMAT BASED METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY VARIES DEPENDENT ON TUMOR TYPE: EXPERIENCE IN 71 PATIENTS. Neuro-Oncology, 2018, 20, i122-i122.	0.6	4
59	QOL-43. CEREBELLAR MUTISM, NEUROCOGNITIVE AND ACADEMIC OUTCOME IN A CONSECUTIVE SAMPLE OF PEDIATRIC CEREBELLAR TUMOR PATIENTS. Neuro-Oncology, 2018, 20, i166-i166.	0.6	0
60	Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3ÂYears with CNS Malignancies. Drugs in R and D, 2017, 17, 469-474.	1.1	6
61	Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Neuro-Oncology, 2017, 19, 1183-1194.	0.6	31
62	From Symptom to Diagnosisâ€"The Prediagnostic Symptomatic Interval of Pediatric Central Nervous System Tumors in Austria. Pediatric Neurology, 2017, 76, 27-36.	1.0	24
63	BMET-08. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE IS FEASIBLE AND SAFE: EXPERIENCE IN 57 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS. Neuro-Oncology, 2016, 18, vi27-vi28.	0.6	1
64	ANGI-14UPDATE ON A METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY FOR RECURRENT MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR. Neuro-Oncology, 2015, 17, v44.1-v44.	0.6	0
65	Levetiracetam as a possible cause of secondary graft failure after allogenic hematopoietic stem cell transplantation. European Journal of Paediatric Neurology, 2015, 19, 75-77.	0.7	7
66	Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients. Journal of Neuro-Oncology, 2014, 120, 139-145.	1.4	58
67	Pharmacokinetics and Toxicity of Intrathecal Liposomal Cytarabine in Children and Adolescents Following Age-Adapted Dosing. Clinical Pharmacokinetics, 2014, 53, 165-173.	1.6	28
68	Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatric Blood and Cancer, 2012, 59, 511-517.	0.8	98
69	Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatric Blood and Cancer, 2010, 54, 681-686.	0.8	33
70	Tumor stabilization under treatment with imatinib in progressive hypothalamicâ€chiasmatic glioma. Pediatric Blood and Cancer, 2009, 52, 476-480.	0.8	11
71	Pharmacokinetics and Safety of Intrathecal Liposomal Cytarabine in Children Aged <3 Years. Clinical Pharmacokinetics, 2009, 48, 265-271.	1.6	34
72	Protein Profiling of the Supratentorial Primitive Neuroectodermal Tumor (PNET) Cell Line PFSK-1. Cancer Genomics and Proteomics, 2004, 1, 125-136.	1.0	1

#	Article	IF	Citations
73	Sociocultural variables have a major impact on participation in patients treated for paediatric posterior fossa tumours. Child: Care, Health and Development, 0, , .	0.8	1